Actively Recruiting
Phase II Study of Axelopran Combined With Nivolumab for Patients With PD-1-Resistant Metastatic Melanoma
Led by John Kirkwood · Updated on 2026-10-19
28
Participants Needed
1
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, clinical activity, and immune effects of combining axelopran, a mu-opioid receptor antagonist, with nivolumab, an immune checkpoint inhibitor, in patients with unresectable or metastatic cutaneous melanoma that no longer responds to PD-1 therapy. This study addresses the challenge of resistance to PD-1 blockers, which limits treatment success in many patients with metastatic melanoma. It also explores how opioid exposure and genetic factors might affect treatment response to guide future personalized immunotherapy approaches. Participants will first receive axelopran alone for one week with a dose increasing up to 15 mg taken by mouth daily. Then, they will enter a combination phase where axelopran at 15 mg daily is given together with nivolumab infusions of 480 mg every four weeks. The nivolumab treatment may continue for up to three years or until the disease worsens. This study is a first-in-human trial combining these drugs to test their joint effects in this patient group. During the study, participants will be monitored for side effects up to 30 days after treatment ends, and their best tumor response will be assessed for up to three years. Additional evaluations will include duration of response, progression-free survival, overall survival up to 4.5 years, and immune-related responses. Researchers will conduct scans, blood tests, and genetic analyses, including looking at opioid receptor genes, to understand how patients respond and to ensure safety throughout the trial.
CONDITIONS
Brief Title
Axelopran and Nivolumab in PD-1-Refractory Metastatic Melanoma
Research Team
D
Danielle Bednarz, RN, BSN
A
Amy Rose, RN, BSN
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here